Company’s 36-month beta value is 5.92.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for APVO is 3.22M, and currently, short sellers hold a 12.00% ratio of that floaft. The average trading volume of APVO on April 16, 2025 was 1.87M shares.
APVO) stock’s latest price update
Aptevo Therapeutics Inc (NASDAQ: APVO) has experienced a decline in its stock price by -7.69 compared to its previous closing price of 1.04. However, the company has seen a fall of -4.95% in its stock price over the last five trading days. accessnewswire.com reported 2025-04-04 that SEATTLE, WASHINGTON / ACCESS Newswire / April 4, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) (“Aptevo” or the “Company”), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, announced the closing of its previously announced offering of 1,764,710 shares of the Company’s common stock in a registered direct offering and warrants to purchase up to 3,529,420 shares of common stock in a concurrent private placement (together with the registered direct offering, the “offering”) at a combined purchase price of $1.19 per share and accompanying warrant. The warrants issued pursuant to the concurrent private placement have an exercise price of $1.19 per share, will be exercisable upon the receipt of stockholder approval and will expire 5 years from the date of stockholder approval.
APVO’s Market Performance
Aptevo Therapeutics Inc (APVO) has seen a -4.95% fall in stock performance for the week, with a -63.64% decline in the past month and a -78.90% plunge in the past quarter. The volatility ratio for the week is 11.92%, and the volatility levels for the past 30 days are at 33.82% for APVO. The simple moving average for the past 20 days is -36.21% for APVO’s stock, with a -87.73% simple moving average for the past 200 days.
Analysts’ Opinion of APVO
Piper Jaffray, on the other hand, stated in their research note that they expect to see APVO reach a price target of $6. The rating they have provided for APVO stocks is “Overweight” according to the report published on October 05th, 2017.
APVO Trading at -62.35% from the 50-Day Moving Average
After a stumble in the market that brought APVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.12% of loss for the given period.
Volatility was left at 33.82%, however, over the last 30 days, the volatility rate increased by 11.92%, as shares sank -63.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -77.93% lower at present.
During the last 5 trading sessions, APVO fell by -4.95%, which changed the moving average for the period of 200-days by -94.96% in comparison to the 20-day moving average, which settled at $1.5049. In addition, Aptevo Therapeutics Inc saw -77.73% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for APVO
The total capital return value is set at -2.62. Equity return is now at value -284.28, with -119.36 for asset returns.
Based on Aptevo Therapeutics Inc (APVO), the company’s capital structure generated 0.49 points at debt to capital in total, while cash flow to debt ratio is standing at -5.14.
Currently, EBITDA for the company is -24.6 million with net debt to EBITDA at 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.72.
Conclusion
In a nutshell, Aptevo Therapeutics Inc (APVO) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
